Lucid Diagnostics' Steady Ascent: Market Access and Growth Pains Lucid Diagnostics Inc.
's second quarter earnings call has revealed a nuanced story of strategic execution and market access progress, tempered by familiar growth pains in the diagnostics sector.
The company's 17% sequential revenue growth is driven by a shift towards testing opportunities with higher collection probabilities, demonstrating its adaptability in laboratory medicine.